Angiogenesis in nodal B cell lymphomas: A high throughput study

Journal of Clinical Pathology

Volumn 60, Issue 5, 2007, Pages 476-482

  Tzankov, Alexandar ^a   Heiss, Simone ^a   Ebner, Stephanie ^a   Sterlacci, William ^a   Schaefer, Georg ^a   Augustin, Florian ^b   Fiegl, Michael ^b   Dirnhofer, Stephan ^c  

^a MEDICAL UNIVERSITY OF INNSBRUCK   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN; PROTEIN P53; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ARTICLE; B CELL LYMPHOMA; CANCER GRADING; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL EVALUATION; COHORT ANALYSIS; FOLLICULAR LYMPHOMA; FOLLOW UP; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MANTLE CELL LYMPHOMA; MORPHOMETRICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY;

AGED; CELL PROLIFERATION; CYCLOOXYGENASE 2; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; LYMPHOMA, MANTLE-CELL; MALE; MICROCIRCULATION; MIDDLE AGED; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 34249873257     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2006.038661     Document Type: Article

References (43)

1. Folkman J, D'Amore PA. Blood vessel formation: what is its molecular basis? Cell 1996;87:1153-5.
2. Weidner N. Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol 1995;147:9-19.
3. Bellamy WT, Richter L, Frutiger Y, et al. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res 1999;59:728-33.
4. Hazar B, Paydas S, Zorludemir S, et al. Prognostic significance of microvessel density and vascular endothelial growth factor (VEGF) expression in non-Hodgkin's lymphoma. Leuk Lymphoma 2003;44:2089-93.
5. Koster A, Raemaekers JM. Angiogenesis in malignant lymphoma. Curr Opin Oncol 2005;17:611-10.
6. Podar K, Anderson KC. The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood 2005;105:1383-95.
7. Gately S, Li WW. Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. Semin Oncol 2004;31(Suppl 7):2-11.
8. Hoper MM, Voelkel NF, Bates TO, et al. Prostaglandins induce vascular endothelial growth factor in a human monocytic cell line and rat lungs via cAMP. Am J Respir Cell MoI Biol 1997;17:748-56.
9. Bono P, Teerenhovi L, Joensuu H. Elevated serum endostatin is associated with poor outcome in patients with non-Hodgkin lymphoma. Cancer 2003;97:2767-75.
10. Pedersen LM, Klausen TW, Davidsen UH, et al. Early changes in serum IL-6 and VEGF levels predict clinical outcome following first-fine therapy in aggressive non-Hodgkin's lymphoma. Ann Hematol 2005;84:510-16.
11. Ho CL, Sheu LF, Li CY. Immunohistochemical expression of basic fibroblast growth factor, vascular endothelial growth factor, and their receptors in stage IV non-Hodgkin lymphoma. Appl Immunohistochem Mol Morphol 2002;10:316-21.
12. Potti A, Ganti AK, Kargas S, et al. Immunohistochemical detection of C-kit (CD117) and vascular endothelial growth factor (VEGF) overexpression in mantle cell lymphoma. Anticancer Res 2002;22:2899-901.
13. Salven P, Orpana A, Teerenhovi L, et al. Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients. Blood 2000;96:3712-18.
14. Vacca A, Ribatti D, Ruco L, et al. Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas. Br J Cancer 1999;79:965-70.
15. Zhao WL, Mourah S, Mounier N, et al. Vascular endothelial growth factor-A is expressed both on lymphoma cells and endothelial cells in angioimmunoblastic T-cell lymphoma and related to lymphoma progression. Lab Invest 2004;84:1512-19.
16. Foss HD, Araujo I, Demel G, et al. Expression of vascular endothelial growth factor in lymphomas and Castleman's disease. J Pathol 1997;183:44-50.
17. Ribatti D, Vacca A, Bertossi M, et al. Angiogenesis induced by B-cell non-Hodgkin's lymphomas. Lack of correlation with tumor malignancy and immunologic phenotype. Anticancer Res 1990;10:401-6.
18. Stewart M, Talks K, Leek R, et al. Expression of angiogenic factors and hypoxia inducible factors HIF 1, HIF 2 and CA IX in non-Hodgkin's lymphoma. Histopathology 2002;40:253-60.
19. Koster A, van Krieken JH, Mackenzie MA, et al. Increased vascularization predicts favorable outcome in follicular lymphoma. Clin Cancer Res 2005;11:154-61.
20. Li HL, Sun BZ, Ma FC. Expression of COX-2, iNOS, p53 and Ki-67 in gastric mucosa-associated lymphoid tissue lymphoma. World J Gastroenterol 2004;10:1862-6.
21. Wun T, McKnight H, Tuscano JM. Increased cyclooxygenase-2 (COX-2): a potential role in the pathogenesis of lymphoma. Leuk Res 2004;28:179-90.
22. Hazar B, Ergin M, Seyrek E, et al. Cyclooxygenase-2 (Cox-2) expression in lymphomas. Leuk Lymphoma 2004;45:1395-9.
23. Bertolini F, Fusetti L, Mancuso P, et al. Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/ SCID mouse model of human high-grade non-Hodgkin lymphoma. Blood 2000;96:282-7.
24. Heider U, Kaiser M, Sterz J, et al. Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma. Eur J Haematol 2006;76:42-50.
25. Pro B, Younes A, Albitar M, et al. Thalidomide for patients with recurrent lymphoma. Cancer 2004;100:1186-9.
26. Stopeck AT, Bellamy W, Unger J, et al. Phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin's lymphoma (NHL): Southwest Oncology Group Study S0108 [abstract]. J Clin Oncol 2005;23:6592.
27. Wang ES, Teruya-Feldstein J, Wu Y, et al. Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo. Blood 2004;104:2893-902.
28. Passalidou E, Stewart M, Trivella M, et al. Vascular patterns in reactive lymphoid tissue and in non-Hodgkin's lymphoma. Br J Cancer 2003;88:553-9.
29. Streubel B, Chott A, Huber D, et al. Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. N Engl J Med 2004;351:250-9.
30. Arias V, Soares FA. Vascular density (tumor angiogenesis) in non-Hodgkin's lymphomas and florid follicular hyperplasia: a morphometric study. Leuk Lymphoma 2000;40:157-66.
31. Bairey O, Zimra Y, Kaganovsky E, et al. Microvessel density in chemosensitive and chemoresistant diffuse large B-cell lymphomas. Med Oncol 2000;17:314-18.
32. Ho CL, Sheu LF, Li CY. Immunohistochemical expression of angiogenic cytokines and their receptors in reactive benign lymph nodes and non-Hodgkin lymphoma. Ann Diagn Pathol 2003;7:1-8.
33. Mazur G, Wrobel T, Dziegiel P, et al. Angiogenesis measured by expression of CD34 antigen in lymph nodes of patients with non-Hodgkin's lymphoma. Folia Histochem Cytobiol 2004;42:241-3.
34. Ridell B, Norrby K. Intratumoral microvascular density in malignant lymphomas of B-cell origin. APMIS 2001;109:66-72.
35. Mitterlechner T, Fiegl M, Mühlböck H, et al. Epidemiology of non-Hodgkin-lymphomas in Tyrol/Austria from 1991 through 2000. J Clin Pathol 2006;59:48-55.
36. Tzankov A, Went Ph, Zimpfer A, et al. Tissue microarray technology: principles, pitfalls and perspectives - lessons learned from hematological malignancies. Exp Gerontol 2005;40:737-44.
37. Joffe ES, Harris NL, Stein H, Vardiman JW, eds. Pathology and genetics of tumours of the haematopoietic and lymphoid system. Lyon: IARC Press, 2001.
38. Turley H, Scott PA, Watts VM, et al. Expression of VEGF in routinely fixed material using a new monoclonal antibody VG1. J Pathol 1998;186:313-18.
39. Gannon JV, Greaves R, Iago R, et al. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J 1990;9:1595-602.
40. Stifter G, Heiss S, Gastl G, et al. Over-expression of tumor necrosis factor-α in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis. Eur J Haematol 2005;75:485-91.
41. Vidal S, Lloyd RV, Moya L, et al. Expression and distribution of vascular endothelial growth factor receptor Flk-1 in the rat pituitary. J Histochem Cytochem 2002;50:533-40.
42. Moller MB, Nielsen O, Pedersen NT. Frequent alteration of MDM2 and p53 in the molecular progression of recurring non-Hodgkin's lymphoma. Histopathology 2002;41:322-30.
43. Subbaramaiah K, Altorki N, Chung WJ, et al. Inhibition of cyclooxygenase-2 gene expression by p53. J Biol Chem 1999;274: 10911-15.